CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 9 enrolled
Drug / intervention
Cyclosporine Adrug
Likely dose
Cyclosporine A 5 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01149759
NCT01149759N/ACompleted
CompareCT.gov

Evaluate Reversal of Pathological Epidermal Phenotype in Severe Atopic Dermatitis With Suppression of Immune Activation During Cyclosporine Therapy

Rockefeller University·interventional·Posted Jun 23, 2010·Updated Mar 27, 2017

In Brief

A clinical study evaluating Cyclosporine A for Atopic Dermatitis and Eczema. Completed, enrolled 9 participants across 1 site.

Detailed Summary

Atopic Dermatitis (AD) or eczema is a chronic relapsing inflammatory disease that affects 1-3% of the adults and up to 25% of the children in the United States. Patients with severe AD will be studied during a 24-week study with systemic cyclosporine (Neoral, capsule form) to evaluate the immune suppression and pathological correlation of cyclosporine A in these patients in order to determine the extent to which immune activation drives the pathological epidermal phenotype.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis, Eczema
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 23, 2010
Enrollment StartJun 1, 2010
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 16.0 years ago

Interventions

Cyclosporine Adrug

5 mg/kg for first 4 weeks, followed by tapering to 1 mg/kg for 12 weeks until discontinuation at 16 weeks